N
TXG icon

Numerai’s 10x Genomics TXG Stock Holding History

Numerai’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-92,360
Closed -$1.51M – 894
2025
Q4 		$1.51M Sell
92,360
-62,465
-40% -$944K 0.18% 168
2025
Q3 		$1.81M Sell
154,825
-90,032
-37% -$1.17M 0.26% 115
2025
Q2 		$2.84M Sell
244,857
-37,301
-13% -$340K 0.41% 75
2025
Q1 		$2.46M Buy
282,158
+124,366
+79% +$1.57M 0.46% 47
2024
Q4 		$2.27M Buy
157,792
+63,176
+67% +$997K 0.62% 36
2024
Q3 		$2.14M Buy
94,616
+48,057
+103% +$994K 0.57% 47
2024
Q2 		$906K Buy
+46,559
New +$1.22M 0.33% 94
2023
Q4 		– Sell
-51,303
Closed -$2.12M – 320
2023
Q3 		$2.12M Sell
51,303
-53,428
-51% -$2.78M 0.7% 50
2023
Q2 		$5.85M Buy
+104,731
New +$5.67M 1.19% 34

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Numerai's TXG Position: Q1 2026 in Review

Numerai sold out of 10x Genomics (TXG) in Q1 2026, closing a stake of 92,360 shares — an estimated $1.51M sold.

Numerai first reported a position in TXG in Q2 2023 and held it in 9 quarters. The position peaked at $5.85M in Q2 2023. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Numerai reported no remaining 10x Genomics position as of Q1 2026 after selling out during the quarter.
  • Numerai sold 92,360 10x Genomics shares in Q1 2026, an estimated $1.51M.
  • Numerai first reported a position in 10x Genomics in Q2 2023 and held it in 9 quarters.
  • Numerai's 10x Genomics position peaked at $5.85M in Q2 2023.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Numerai's 13F filing for Q1 2026, filed 15 May 2026.